Top

International Journal of Colorectal Disease

Published in:

01-01-2008 | Original Article

Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy

Authors: Cem Terzi, Aras Emre Canda, Ozgul Sagol, Koray Atila, Devrim Sonmez, Mehmet Fuzun, Ilknur B. Gorken, Ilhan Oztop, Funda Obuz

Published in: International Journal of Colorectal Disease | Issue 1/2008

Abstract

Purpose

The ability to predict response to chemoradiotherapy before the treatment may allow protecting poorly responding patients from the side effects of neoadjuvant treatment. Several molecular markers have been proposed to radio and chemosensitivity of rectal cancer. In this study, from pre-irradiation tumor biopsies, a novel and promising candidate factor survivin, and p53 and Ki-67 were assessed as predictors of response to preoperative chemoradiotherapy.

Materials and methods

Expression of each marker was evaluated by immunohistochemistry on pretreatment biopsies from 37 patients having rectal cancer treated with preoperative chemoradiotherapy and curative surgery. Treatment response was assessed histopathologically in the resected surgical specimen.

Results

There was no correlation between expression of p53, Ki-67, and survivin with response to preoperative chemoradiotherapy and prognosis.

Conclusions

Our data suggest that these molecular markers are not helpful to identify patients who would have benefit from neoadjuvant treatment of rectal cancer. Further investigations are necessary to select patients for preoperative treatment based on analysis of the preoperative biopsies.

Minsky BD, Cohen AM, Kemeny N et al (1992) Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 10:79–84PubMed

Minsky BD, Cohen AM, Kemeny N et al (1993) The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 71:3486–3492PubMedCrossRef

Marsh RD, Chu NM, Vauthey JN et al (1996) Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 78:217–225PubMedCrossRef

Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef

Valentini V, Coco C, Picciocchi A et al (2002) Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664–674PubMedCrossRef

Reerink O, Karrenbeld A, Plukker JT et al (2004) Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res 24:1217–1221PubMed

Theodoropoulos G, Wise WE, Padmanabhan A et al (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45:895–903PubMedCrossRef

Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P (2002) Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94:1121–1130PubMedCrossRef

Ruo L, Tickoo S, Klimstra DS et al (2002) Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236:75–81PubMedCrossRef

10.

Wheeler JM, Dodds E, Warren BF et al (2004) Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 47:2025–2031PubMedCrossRef

11.

Crane CH, Skibber JM, Feig BW et al (2003) Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97:517–524PubMedCrossRef

12.

Ammann K, Kirchmayr W, Klaus A et al (2003) Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum. Arch Surg 138:257–261PubMedCrossRef

13.

Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858PubMedCrossRef

14.

Peeters KCMJ, van de Velde CJH, Leer JWH et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients. J Clin Oncol 23:6199–6206PubMedCrossRef

15.

Birgisson H, Pahlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131PubMedCrossRef

16.

Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ (2006) Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 32:55–64PubMedCrossRef

17.

Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49PubMed

18.

Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRef

19.

Tiefenbacher U, Wenz F (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. Strahlenther Onkol 177:682–684PubMed

20.

Rodel F, Hoffmann J, Grabenbauer GG et al (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178:426–435PubMedCrossRef

21.

Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F (2003) Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55:1341–1347PubMedCrossRef

22.

Rodel F, Hoffmann J, Distel L et al (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881–4887PubMedCrossRef

23.

Sjödahl R (1997) Do we need adjuvant treatment for rectal cancer. Ann Med 29:91–93PubMed

24.

Zaheer S, Pemberton JM, Farouk R et al (1998) Surgical treatment of adenocarcinoma of the rectum. Ann Surg 227:800–811PubMedCrossRef

25.

Sobin LH, Wittekind Ch (eds) (2002) International Union Against Cancer (UICC): TNM classification of malignant tumors, 6th edn. Wiley–Liss, New York

26.

Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479–1482PubMedCrossRef

27.

Quirke P, Durdey P, Dixon MF, Williams NS (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical excision. Histopathological study of lateral tumor spread and surgical excision. Lancet 2:996–999PubMedCrossRef

28.

Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York

29.

Begg CB, Carbone PP (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52:1986–1992PubMedCrossRef

30.

Gilcrease MZ, Truong L, Brown RW (1996) Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol 27(12):1355–1360PubMedCrossRef

31.

Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J colorectal Dis 12:19–23PubMedCrossRef

32.

Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garcia-Aguilar J (2000) Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 43:451–459PubMedCrossRef

33.

Fu CG, Tominaga O, Nagawa H et al (1998) Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 41(1):68–74PubMedCrossRef

34.

Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P (2002) Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 100:131–135PubMedCrossRef

35.

Kandioler D, Zwrtek R, Ludwig C et al (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235:493–498PubMedCrossRef

36.

Lopez-Crapez E, Bibeau F, Thezenas S et al (2005) p53 status and response to radiotherapy in rectal cancer: a prospective analysis. Br J Cancer 92:2114–2121PubMedCrossRef

37.

Thompson LH, Humphrey RM (1970) Proliferation kinetics of mouse L-P59 cells irradiated with ultraviolet light: a time-lapse photographic study. Radiat Res 41(1):183–201PubMedCrossRef

38.

Tolmach LJ (1961) Growth patterns in x-irradiated HeLa cells. Ann N Y Acad Sci 95:743–757PubMedCrossRef

39.

Rau B, Sturm I, Lage H et al (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21:3391–3401PubMedCrossRef

40.

Rodel C, Grabenbauer GG, Papadopoulos T et al (2002) Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52:294–303PubMedCrossRef

41.

Key G, Becker MH, Baron B et al (1993) New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68:629–636PubMed

42.

Schalzen T, Gerdes J (2002) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRef

43.

Kim NK, Park JK, Lee KY et al (2001) p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 8:418–424PubMedCrossRef

44.

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRef

45.

Peltenburg LT (2000) Radiosensitivity of tumor cells. Oncogenes and apoptosis. Q J Nucl Med 44:355–364PubMed

46.

Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300–304PubMedCrossRef

47.

Shin S, Sung BJ, Cho YS et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123PubMedCrossRef

48.

Monzo M, Rosell R, Felip E et al (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17:2100–2104PubMed

49.

Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808–1812PubMed

50.

Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127–134PubMed

51.

Kato J, Kuwabara Y, Mitani M et al (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92–95PubMedCrossRef

52.

Kappler M, Kohler T, Kampf C et al (2001) Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 95:360–363PubMedCrossRef

53.

Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645–650PubMedCrossRef

54.

Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071–5074PubMed

55.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

56.

Blagosklonny MV (2004) Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 23:2967–2975PubMedCrossRef

57.

Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721–729PubMedCrossRef

58.

Meyn RE, Stephens LC, Milas L (1996) Programmed cell death and radioresistance. Cancer Metastasis Rev 15:119–131PubMedCrossRef

59.

Meyn RE, Stephens LC, Ang KK et al (1993) Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 64:583–591PubMedCrossRef

60.

Abe T, Sakaguchi Y, Ohno S et al (2001) Apoptosis and p53 overexpression in human rectal cancer; relationship with response to hyperthermo-chemo-radiotherapy. Anticancer Res 21:2115–2120PubMed

61.

Scott N, Hale A, Deakin M et al (1998) A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol 24:169–173PubMedCrossRef

62.

Rich TA, Sinicrope F, Stephens C et al (1996) Down staging of T3 rectal cancer after pre operative infusional chemoradiation is correlated with spontaneous apoptosis index and Bcl 2 staining. Int J Radiat Oncol Biol Phys 36:259CrossRef

63.

Smith FM, Reynolds JV, Kay EW et al (2006) COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 64:466–472PubMedCrossRef

64.

Li F, Yang J, Ramnath N, Javie MM, Tan D (2005) Nuclear and/or cytoplasmic expression of surviving: what is the significance. Int J Cancer 114:509–512PubMedCrossRef

Title: Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy
Authors: Cem Terzi
Aras Emre Canda
Ozgul Sagol
Koray Atila
Devrim Sonmez
Mehmet Fuzun
Ilknur B. Gorken
Ilhan Oztop
Funda Obuz
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 1/2008
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-007-0376-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2008

The effect of estrogen on hepatic microcirculation after ischemia/reperfusion

Ileus due colon endometriosis and the role of MRI scan

Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer

Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients

Clear cell adenocarcinoma: a rare variant of primary colonic tumour

Long-segment hypoplasia of the left hemicolon 4 months after sigmoid resection and loop transversostomy in a patient with intestinal endometriosis